In relation to the previouspost referencing the announcement, it’s worth taking a minute and having a good look at the numbers. 1 million STI’s contracted daily around the globe and 376 million annually for the four mentioned. That’s roughly one in 21 people will contract an STI annually, and with annual growth of 7% equating to another 26million and growing, the numbers are staggering. Coronavirus cases up to 40million since the start of the year. 1/9 of annual STI’s. Puts it into perspective. With the ability to test for numerous STI’s in one hit, this will be the high growth market for GSS. ”These registrations are expected before the end of 2020” in both Australia aand Europe. Let’s hope they are correct with this one. If they can gain traction in Europe with their products on the back of coronavirus, the sky’s the limit.
GSS Price at posting:
$1.95 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)